Ultra-small superparamagnetic iron oxide contrast agents for lymph node staging of high-risk prostate cancer

被引:22
作者
Czarniecki, Marcin [1 ]
Pesapane, Filippo [2 ,3 ,4 ]
Wood, Bradford J. [3 ,4 ]
Choyke, Peter L. [1 ]
Turkbey, Baris [1 ]
机构
[1] NCI, Mol Imaging Program, NIH, Bethesda, MD 20892 USA
[2] Univ Milan, Postgrad Sch Radiodiagnost, Milan, Italy
[3] NCI, Ctr Intervent Oncol, Bethesda, MD 20892 USA
[4] NIH, Radiol Imaging Sci, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
Ultrasmall superparamagnetic particles of iron oxide (USPIO); lymph node (LN); prostate cancer; magnetic resonance imaging (MRI); DIAGNOSTIC PERFORMANCE; MR LYMPHANGIOGRAPHY; METASTASES; PARTICLES; BLADDER; NANOPARTICLES; LYMPHOGRAPHY; METAANALYSIS; FERUMOXYTOL; FERUMOXTRAN;
D O I
10.21037/tau.2018.05.15
中图分类号
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
摘要
Ultrasmall superparamagnetic particles of iron oxide (USPIOs) imaged with magnetic resonance imaging (MRI) have been proposed as an experimental method for visualizing lymph node (LN) metastases. The method does not require ionizing radiation, yet can detect small nodes that are involved with metastases. USPIOs are naturally taken up by macrophages that deposit in the normal LN creating a low signal region in normal areas; areas within the node that do not show this loss of signal are likely involved by tumor although there can be other causes (fibrosis or inflammation). However, the lack of approved USPIOs that are clinically available hinders adoption and larger studies. The proposed indications for USPIO MRI, including specific compounds and imaging methods are discussed.
引用
收藏
页码:S453 / S461
页数:9
相关论文
共 50 条
[1]   Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: Phase III safety and efficacy study [J].
Anzai, Y ;
Piccoli, CW ;
Outwater, EK ;
Stanford, W ;
Bluemke, DA ;
Nurenberg, P ;
Saini, S ;
Maravilla, KR ;
Feldman, DE ;
Schmiedl, UP ;
Brunberg, JA ;
Francis, IR ;
Harms, SE ;
Som, PM ;
Tempany, CM .
RADIOLOGY, 2003, 228 (03) :777-788
[2]   Safety and efficacy of total dose infusion of 1,020 mg of ferumoxytol administered over 15 min [J].
Auerbach, Michael ;
Strauss, William ;
Auerbach, Sarah ;
Rineer, Stella ;
Bahrain, Huzefa .
AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (11) :944-947
[3]   Comparison of rates of reported adverse events associated with i.v. iron products in the United States [J].
Bailie, George R. .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2012, 69 (04) :310-320
[4]   ESUR prostate MR guidelines 2012 [J].
Barentsz, Jelle O. ;
Richenberg, Jonathan ;
Clements, Richard ;
Choyke, Peter ;
Verma, Sadhna ;
Villeirs, Geert ;
Rouviere, Olivier ;
Logager, Vibeke ;
Futterer, Jurgen J. .
EUROPEAN RADIOLOGY, 2012, 22 (04) :746-757
[5]   Safety and Tolerability of Ultrasmall Superparamagnetic Iron Oxide Contrast Agent Comprehensive Analysis of a Clinical Development Program [J].
Bernd, Hamm ;
De Kerviler, Eric ;
Gaillard, Sophie ;
Bonnemain, Bruno .
INVESTIGATIVE RADIOLOGY, 2009, 44 (06) :336-342
[6]   Combined Ultrasmall Superparamagnetic Particles of Iron Oxide-Enhanced and Diffusion-weighted Magnetic Resonance Imaging Facilitates Detection of Metastases in Normal-sized Pelvic Lymph Nodes of Patients with Bladder and Prostate Cancer [J].
Birkhaeuser, Frederic D. ;
Studer, Urs E. ;
Froehlich, Johannes M. ;
Triantafyllou, Maria ;
Bains, Lauren J. ;
Petralia, Giuseppe ;
Vermathen, Peter ;
Fleischmann, Achim ;
Thoeny, Harriet C. .
EUROPEAN UROLOGY, 2013, 64 (06) :953-960
[7]  
Bordat C, 2000, J MAGN RESON IMAGING, V12, P505, DOI 10.1002/1522-2586(200009)12:3<505::AID-JMRI18>3.0.CO
[8]  
2-A
[9]   Recent advances in iron oxide nanocrystal technology for medical imaging [J].
Corot, Claire ;
Robert, Philippe ;
Idee, Jean-Marc ;
Port, Marc .
ADVANCED DRUG DELIVERY REVIEWS, 2006, 58 (14) :1471-1504
[10]   Ten Things You Might Not Know about Iron Oxide Nanoparticles [J].
Daldrup-Link, Heike E. .
RADIOLOGY, 2017, 284 (03) :616-629